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Prior to the development of benzodiazepines (BZDs) in the 1950’s, a class of 
drugs known as tranquilizers were used in psychiatry to treat patients experiencing 
anxiety and fear as well as more challenging states of psychosis such as schizophrenia.1,2  
The first minor tranquilizer and anxiolytic compound that was widely used in the United 
States and much of the world was meprobamate in the 1950s.   Meprobamate is a 
carbamate compound typically administered in tablet form and ingested orally as its route 
of administration.  Meprobamate is also the major metabolite of the drug carisoprodol, 
which is sold under the brand name Soma ®.3,4,5  Both meprobamate and carisoprodol are 
schedule IV substances under the Controlled Substance Act as there is reported abuse 
with each substance. 6,7 
The primary goal of this research is to determine whether collected patient data 
reflects appropriate usage of their carisoprodol prescription in treatment of anxiety and if 
urine drug testing (UDT) and specimen validity testing (SVT) can support or refute the 
effectiveness of a patient’s treatment by measuring resulting meprobamate concentration.  
For the purpose of this study, a data set consisting of a population that was prescribed 
carisoprodol was provided by a therapeutic drug-testing lab.  Qualitative results include a 
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known prescription for carisoprodol, the presence of carisoprodol as well as the main 
anxiolytic metabolite meprobamate, whether a patient’s sample passed or failed SVT, and 
the sex of the individual.  Quantitative results include initial and reported drug dosage, 
target analyte concentration, age, SVT result and body mass index (BMI). 
The lab used liquid chromatography tandem mass spectrometry (LC-MS/MS) to 
run analysis of urine specimen.8  Data analysis was conducted using R Studio version 
3.5.1 (R Foundation, Vienna, Austria).  R Studio is a statistical program that is utilized 
for computation and production of graphics.9   Statistical analysis and sub setting was used 
to find relationships and trends of meprobamate concentrations as they relate to age, 
BMI, dosage and SVT parameters.  
In this study of 1,672 patients, 1,067 were female and 685 males with females 
having 63.8% of the patient population.  Of the overall population, 33.3% had a 
carisoprodol dose between 700-1050 mg, equivalent to 2 to 3 doses of 350 mg, in tablet 
form daily.  70.5% of the patient population was deemed overweight in terms of BMI yet 
had a lower average meprobamate concentration in urine compared to normal weight 
patients.  The majority of participants in the study, 82.5% of females and 84.3% of males, 
who had a prescription for carisoprodol were between the ages of 40 and 69. SVT testing 
parameters were used to filter patient data a second time.  Certain samples fell outside of 
accepted ranges for pH, creatinine and specific gravity.  Of all 1,672 submitted samples, 
18.2% failed at least one parameter or contained an illicit substance.  The average 
meprobamate concentration for males was 26,896 ng/mL (530-292,133 ng/mL range) and 
the average concentration for females was 28,802 ng/mL (500 to 336,853 ng/mL range). 
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This research highlights the need for compliance drug testing to ensure that patients are 
taking their prescribed dose appropriately and monitoring for signs of abuse.  The trends 
discovered in this research can be used to evaluate known carisoprodol dosing and relate 
it to meprobamate concentration in urine drug testing.  There are likely to be variations in 
patients’ metabolism and overall health but having a sense of how much carisoprodol to 
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Prior to the development of benzodiazepines (BZDs) in the 1950’s, a class of 
drugs known as tranquilizers were used in psychiatry to treat patients experiencing 
anxiety and fear as well as more challenging states of psychosis such as schizophrenia.1,2  
This class of drugs can be categorized in two sub-categories: major and minor 
tranquilizers.  Major tranquilizers, also called neuroleptics, were generally reserved for 
individuals who were at risk for harming themselves or others due to psychosis, delusion, 
or hallucination.3  In contrast, minor tranquilizers, also called anxiolytics or antianxiety 
medication, closely mimic the physiological effects of today’s BZDs.  Minor 
tranquilizers are often prescribed and are used as anticonvulsants, sedatives, and 
hypnotics.3  To what extent these compounds affect an individual is dependent on the 
dose an individual takes with lower doses having only minor anxiolytic effects and higher 
doses resulting in more sedative effects.  Based on the physiological effects that minor 
tranquilizers elicit in a given individual, these compounds can also be characterized as 
central nervous system (CNS) depressants.3,4 
The first minor tranquilizer and anxiolytic compound that was widely used in the 
United States and much of the world in the 1950s was meprobamate.1,2   Meprobamate is a 
carbamate compound typically administered in tablet form and ingested orally as its route 
of administration.  Although marketed initially as a non-habit-forming anxiolytic, many 
cases of abuse and withdrawal were reported within the first few years of clinical use.4 
The barbiturate-like effects that the drug elicits in the body prompted label warnings 
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against compounding CNS depressants (alcohol), operating machinery and possible 
mood-changing capabilities, all of which has cause the drug to be since been scheduled as 
a Schedule IV controlled substance under the Controlled Substances Act (CSA).  A 
Schedule IV substance means that the substance has potential for abuse and 
psychological dependence on a lesser scale than Schedules I-III.6,7,10  Due to its abuse 
potential, meprobamate was removed from both the EU and Canadian markets.  It was 
due to the large number of reported cases of abuse and its large scope of use that 
meprobamate was then replaced with benzodiazepines, which were determined to be less 
toxic and less likely to result in dependence.11  
To try to decrease the abuse potential of anxiolytic agents like meprobamate, the 
drug carisoprodol was synthesized in 1959.  Carisoprodol is a skeletal muscle relaxant 
that metabolizes to meprobamate and can result in sedative effects on the body that 
compounds when combined with BZDs or alcohol.  Carisoprodol is marketed as Soma ® 
and the recommended dose is a 350 mg tablet three times per day.  The euphoria induced 
by drug-drug interactions, the effect on psychomotor coordination when operating a 
vehicle, as well as the intense withdrawal symptoms reported all contributed to 
carisoprodol being scheduled as a schedule IV substance at the federal level in the United 
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1.2 Pharmacology of Meprobamate 
1.2.1 Pharmacodynamics  
The pharmacodynamics of a drug are important as it is how that drug interacts 
biochemically, physiologically, and molecularly within the body of an individual.  These 
interactions occur when certain portions of a drug of interest are bound by receptor 
proteins in the body resulting in chemical interactions that can elicit physiological effects 
that a drug is designed to treat.  Meprobamate is a primary metabolite of carisoprodol 
which dealkylates to meprobamate with an isopropyl group removed by the enzyme 
protein cytochrome P450 2C19 (CYP2C19).12  Meprobamate modulates gamma 
aminobutyric acid Type A (GABAA) receptors and mimics the effect of barbiturates by 
slowing the CNS upon binding to these receptors.11,12   Once introduced into the body and 
upon binding to GABAA receptors, physiological effects can include sedation, loss of 
balance, and increased reaction time.  
 
Figure 1: Conversion of carisoprodol to meprobamate via CYP2C19 12 
 
1.2.2 Pharmacokinetics 
How a drug is absorbed, distributed, metabolized, and excreted is also known as 
that drug's pharmacokinetics.  The rate at which this process happens is dependent upon 
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the dose of the drug, chemical properties of the drug such as solubility, pKa and pKb 
values, and how the drug is administered.  Meprobamate is administered orally in tablet 
or powder form as well as being the primary metabolite of carisoprodol, which has been 
marketed as Soma®.  Meprobamate, once ingested orally, is absorbed through the 
gastrointestinal tract, and subsequently is absorbed into the liver.  Meprobamate reaches 
peak blood volume between 1 and 3 hours with concentrations ranging from 0.4 mg/L to 
464.4 mg/L.13.18   Meprobamate has a volume of distribution (Vd) or 0.7L/kg. Between 14 
and 24% of the drug is protein bound which then is metabolized by the liver.  Once 
metabolized, only between 10 and 20% of meprobamate is excreted intact by the kidneys. 
The half-life of meprobamate ranges between 6 and 17 hours and the drug is hydrolyzed 
to hydroxymebrobamate, an inactive metabolite which is also excreted in urine.14,15 
 
1.3 Therapeutic Drug Monitoring  
1.3.1 Drug Testing 
When healthcare professionals prescribe drugs designed to be of therapeutic value 
to their patients, it is not uncommon for periodic testing to be included in the evaluation 
of whether the drug is aiding the patient at the prescribed dosage and to determine if the 
drug is being taken appropriately.  The process of testing patient blood to determine drug 
of interest concentration is known as therapeutic drug monitoring (TDM).16  This process 
of using TDM to determine an effective and appropriate dose for a patient has multiple 
functions.  Workplace or probation officers also use TDM to ensure compliance with 
abstaining from illicit drug use.  To accurately gauge both parent drug and metabolite 
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concentration within a given individual, it is important that the patient is given sufficient 
time to ingest the prescribed dose on multiple occasions to obtain a clinically significant 
measurement of concentration in the blood.  For this reason, any changes in the patient’s 
drug or metabolite concentration, dosage regimen and demographics are recorded at each 
instance of testing to provide accurate clinical information to readily assess the 
effectiveness of treatment. 17 
Another type of drug monitoring that can occur is urine drug testing (UDT).  
Urine testing is another effective method of monitoring compliance with prescribed drugs 
used for therapeutic means (compliance testing) as well as detection of abuse of that drug 
or other illicit substances (forensic testing). 19,20   Urine contains waste substances 
removed from the blood by the kidneys and is one of the main means of excretion for 
humans, making it an ideal biological fluid to screen for drugs as it is in liquid form and 
can be collected, stored, and analyzed easily compared to other biological fluids (e.g., 
blood).  The window of detection for drugs and their metabolites in urine is typically 1 to 
3 days or longer depending on the metabolite, which aids in the ability to screen for drugs 
of interest. 19,20 
 
1.3.2 Specimen Validity Testing  
 When testing urine samples in either compliance or forensic settings, individuals 
may try to manipulate the collection of their sample.  Individuals will attempt to 
manipulate their sample in order to pass a drug compliance test for probation or to secure 
a new occupation as they can try to hide illicit drug use or noncompliance of prescribed 
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medications.  To ensure integrity of collected urine samples specimen validity testing 
(SVT) is conducted.  SVT is routinely made up of pH, specific gravity, and creatinine 
concentration in urine to ensure the sample integrity, for example was it diluted?  Is it 
even from a human being?  When compliance or forensic drug testing on a urine 
specimen is conducted, immediate observations on the specimen’s appearance, odor, and 
color can be recorded.  Further testing using SVT may measure the initial temperature at 
collection, specific gravity, pH, and creatinine levels of that given sample.24  Accepted 
normal levels of each criteria are as follows: Creatinine between 20-500 mg/dL 
(milligrams per decaliter), specific gravity between 1.016 and 1.026, a pH level between 
4.5-8.0, and a temperature within four minutes of specimen collection between 90 °F to 
100 °F.19,20 
Individuals will attempt to deceive potential employers, their healthcare 
providers, or probation officers by altering their submitted samples.  Adulterated samples 
are those that have been manipulated with detoxing agents to aid in passing a drug 
screening test.  Adulterants can be added to urine prior to specimen submission and result 
in pH levels either under 3 or above 11 and nitrite concentrations above the 500 mcg/mL 
threshold.  Dilution is another tactic individuals have used to alter specimen validity 
where large quantities of water or other diluents can be ingested prior to producing a 
urine specimen in order to lower the overall concentration of drugs of interest or abuse. 
Creatinine levels between 2 and 20 mg/dL and specific gravity between 1.0020-1.0030 
are consistent with a diluted sample.  Substituted specimens may include synthetic urine 
or urine-like mixtures that are submitted in place of the individual's actual urine 
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specimen.19,20,21  When submitted specimens have creatinine levels less than 2 mg/dL and 
specific gravity between 1.0020 and 1.0030 the sample is considered to be substituted. 
An invalid specimen will have inconsistent values for creatinine and specific gravity as 
well as pH and nitrite values in ranges that do not coincide with valid biological 
specimen and will not be accepted.  An invalid specimen may also include other 
substances or chemicals that will alter SVT results.20,21 
 
1.3.3 Confirmatory testing 
 To confirm the presence of analytes or drugs of interest, biological samples have 
to be introduced into instrumentation in a way that does not corrupt the integrity of the 
sample or cause damage to the instrument being used for analysis.  Liquid 
chromatography-tandem-mass spectrometry (LC-MS/MS) can be used to confirm the 
presence of a target analyte in solution and its concentration.  The liquid chromatography 
portion of the instrument is important in separating component analytes of a given 
solution using pumps to drive a mobile phase solvent and a portion of the sample through 
a stationary phase column at high pressure.22,23  The chemical interactions between the 
analytes within the sample being injected into the column and the stationary phase will 
determine how quickly or slowly a given analyte will elute through the column (e.g., 
retention time).  This can be achieved using either an isocratic elution, where the solvent 
remains the same throughout the duration of the run, or with a gradient elution, using 
multiple solvents at differing percentages to enhance or optimize the amount of time per 
injection and also improve analyte separation.  Based on the retention time and intensity 
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that an analyte is detected, a chromatogram is created in real time that can be viewed on 
the computer output.22,23 
 Once the analyte elutes off the column it is directed to the mass spectrometer 
where liquid molecules are passed through a nebulizer creating small droplets in the form 
of an aerosol that becomes charged when receiving high voltage.  This charged aerosol is 
directed to a vacuum that carries the charge in an electrical current that then can be read 
by the data system.  As this occurs, the ions are separated and detected based on their 
mass-to-charge ratio (m/z).  The relative m/z ratios are plotted along with the total 
amount or signal strength of each ion fragment producing a mass spectrum.  This mass 
spectrum will highlight mass to charge ratios equivalent to both the molecular weight of 
the analyte and fragments of the analyte resulting from gas phase interactions with an 
inert gas.  The transitions from the whole molecule to the various fragments that occur 
most frequently are called major ions and can be used to help elucidate the true identity 
of the molecule of interest. 22,23,33 
1.4 Research Objective 
 Carisoprodol and meprobamate have been utilized to regulate anxiety since the 
1950’s.  Meprobamate is of particular interest due to its potential for abuse, which is a 
reason that healthcare professionals follow up with patients who they prescribe the 
anxiolytic agent to.  Due to the potential for abuse of meprobamate, it is important that 
TDM and UDT are used to ensure compliance with discussed treatment plans and to 
maintain appropriate dosing given a patient’s sex, age and overall health.25,26,27  The 
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objective of this paper is to determine whether collected patient data from appropriate 
usage of carisoprodol in treatment of anxiety including UDT and SVT can support or 
refute adherence of patients to their treatment plan.  Qualitative results include a known 
prescription for carisoprodol, the presence of carisoprodol as well as the main anxiolytic 
metabolite meprobamate, whether a patient’s sample passed or failed SVT, and the sex of 
the individual.  Quantitative results include initial and reported drug dosage, target 
analyte concentration, age, and BMI.  The initial dose of carisoprodol will be the amount 
of carisoprodol ingested per day at the beginning of treatment where the final dose of 
carisoprodol will be the amount ingested per day as treatment progresses.  The goal of 
this research is to determine the relationship between carisoprodol dosage ingested by a 
patient and the amount of the main metabolite of carisoprodol, meprobamate, is present 
in a provided urine specimen.  
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2. MATERIALS AND METHODS 
2.1 Sample Preparation 
The method of sample collection and preparation was described in a previous 
study conducted by Enders et. al (2018) where an LC-MS/MS method was validated.8  
Enders et. al., detail their work as follows: a meprobamate-D7 internal standard was 
purchased from Cerillant Corporation (Round Rock, TX, USA) at a concentration of 100 
µg/mL.  This stock solution was further diluted along with the other internal standards to 
a final concentration of 1,000 ng/mL in water.  For use as calibrators (ranging from 100 
ng/mL to 100,000 ng/mL) and quality control standards (3000 ng/mL), the standards 
were prepared based on the class of drug they were categorized as and further diluted in 
drug-free human urine which was purchased from UTAK Laboratories (Valencia, CA, 
USA).  The dynamic range of calibrators used in this study ranged from 10-100,000 
ng/mL.  The enzyme solution used in this study required a dilution of IMCSzyme ® ß-
glucouronidase solution (IMCS, Irmo, SC) in 0.02 M sodium phosphate buffer at a pH of 
7.5 and final concentration of 10,000 ng/mL.  For samples, 30 µL (microliters) of the 
patient urine sample, 30 µL of 1000 ng/mL meprobamate-D7 internal standard and 120 
µL of enzyme solution were added to a well plate and then incubated at 60 °C for an hour 
to allow the samples to undergo hydrolysis.  Solid phase extraction was then used where 
each sample was washed with 350 µL of water, 200 µL of 100mM HCl and a subsequent 
wash of 250 µL with water.  These samples were then eluted with 300 µL of 80:18:2 
dichloromethane:isopropanol:ammonium hydroxide and then dried under nitrogen. 
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Reconstitution of the original 30 µL of sample was completed by diluting it 10x using 
300 µL 10% methanol:90 % water to then be analyzed by LC-MS/MS.8  
 
2.2 Analytical Method 
Analysis of prepared samples was performed on an Agilent LC-MS/MS 6460 
system incorporating an Agilent 1290 Infinity II chromatographic system.8  All validation 
results were included in the report produced by Enders et al.8  The method utilizes a 5mM 
(millimolar) ammonium formate in 10% methanol with 0.1% formic acid solvent for 
solvent A and a 5 mM ammonium formate in methanol with 0.1% formic acid for solvent 
B. The time for one complete cycle took approximately 6.5 minutes per sample run.  The 
flow rate used was 0.8 mL/min.  A Phenomenex (Torrence, CA, USA) Kinetex 2.6 µm 
Phenyl-Hexyl 100Å, 50 x 4.6 mm (00B-4495-EO) LC column was used in the analysis.  
Injection volume was set to 15 µL and column temperature was set to 30 °C in this 
method.8  
 
2.3 Data Analysis 
 The patients undergoing treatment with meprobamate submitted their urine 
samples for quantitative LC-MS/MS to determine compliance with prescription.  Data 
analysis was conducted using R Studio version 3.5.1 (R Foundation, Vienna, Austria).  R 
Studio is a statistical program that is utilized for computation and production of 
graphics.9  To properly identify meprobamate concentrations and compliance of 
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carisoprodol prescription, the analytical testing data was narrowed to coincide with the 
following parameters: 
 
1. Only patient data that had complete demographic information (e.g., weight, 
height, sex) were included. 
2. Only patient data that included the presence of meprobamate in their urine 
samples were included 
3. Only patients who had quantifiable and exact meprobamate concentrations 
were included. 
The removal of some patient results was done to omit incomplete or inaccurate data to 
provide the best overall understanding on meprobamate concentration in urine specimens.  
For the following parameters, statistical analysis was utilized to gain a better 
understanding of the overall patient data for carisoprodol prescription and subsequent 
meprobamate concentration: prescribed initial and final dose, BMI, age, and whether they 
passed SVT parameters.  




)  =  
𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
ℎ𝑒𝑖𝑔ℎ𝑡 (𝑚2)
     (Equation 1) 
BMI was used to split the population into three categories: underweight, normal 
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Table 1. BMI Chart. Classifications were used to separate patients based upon BMI. 
Classification BMI (kg/m2) 
Underweight < 18.4 
Normal weight 18.5-24.9 
Overweight ≥ 25 
  
After evaluating the prescribed dosage of carisoprodol for each patient involved 
in the study, different dosage ranges were compiled to organize and observe data trends 
that occurred in terms of resulting meprobamate concentration in provided urine 
specimens.  Dosage groups (Table 2) were based on observing dosages reported 
throughout therapeutic usage of carisoprodol.  Carisoprodol prescriptions increase in 
dosage by increments of 350 mg, though it was observed that some patients were treating 
themselves with half-doses, also influencing the ranges in Table 2. 
Table 2: Carisoprodol Dose Ranges 







Comparison between age groups (Table 3) were also considered to determine the 
relationship between meprobamate concentration in urine and increasing age of patient.  
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The age groups will be used to further observe meprobamate concentration relationships 
in urine specimens.  Furthermore, urine specimens will be evaluated for compliance with 
SVT testing parameters (Table 4) to determine what portion of the population in this 
study was reported as failing the SVT parameters initially and which samples fell outside 
SVT parameters after closer inspection of creatinine, specific gravity or pH. 
 
Table 3. Age groups to subdivide population 









Table 4: SVT parameters for acceptable urine specimen 
Parameter Accepted Range 
pH 4.5-8 
Creatinine <20 mg/dL 
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3. RESULTS 
3.1 Study Population (Males and Females) 
After starting with an initial patient list of 2,088 patients who were prescribed 
carisoprodol for therapeutic means, filtering of the list to only include complete patient 
data points of males and females reduced the total data points to 1,672.  The resulting 
population of patients included 1,067 females (63.8% of the total population) and 605 
males (36.2% of the total population).  The population had an overall age range from 21 
to 88 years of age with an average age of 55.29 years of age.  The dosages of 
carisoprodol occurred in increments of 350 mg where initial dose concentration with an 
average of 715.8 mg (0-4200 mg range) and median of 700 mg.  As treatment progressed, 
the average dosage of the final dose category was 946 mg (0-5250 mg range) and a 
median of 1050 mg, meaning on average patients were taking a 350 mg carisoprodol 
tablet or powder three times per day to treat anxiety. 
Concentrations of meprobamate seen in urine specimens among the population 
showed a minimum concentration of 500 ng/mL and a maximum concentration of 
336,853 ng/mL.  The average concentration of meprobamate found present in urine 
specimens for the entire population of the study was 28,112 ng/mL with a median 
concentration of 16,917 ng/mL.  Data points prior to filtering of incomplete data sets for 
patients had concentrations that were inexact (listed as >100,000 ng/mL) or were greater 
than 5 times the mean concentration, so those points were not included in the calculation 
of meprobamate concentrations for the population.  
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3.1.2 Study Population Dosing  
For the initial dose of carisoprodol prescribed to the patients in this study, the 
relationship between resulting meprobamate concentration in urine specimens and the 
initial dose is highlighted by Figure 2.  The minimum reported concentration of 
meprobamate for the initial dose category was 500 ng/mL (the analytical cutoff for 
minimum concentration) and a maximum concentration of meprobamate in urine was 
336,853 ng/mL in a patient who fell in the 1050-1400 mg initial dose category.  An 
average initial dose to meprobamate concentration was 29,344 ng/mL.  Certain samples 
in the population needed to be diluted and rerun to attain a meprobamate concentration 
within the analytical range of the original LC-MS/MS methodology.8  
Of the 1,672 patients in the study, 447 had an initial dose in the 0-300 mg dosing 
range, 431 patients had an initial dose in the 350-700 mg dosing range, 503 patients had 
an initial dose in the 700-1050 mg range, 270 patients had an initial dose in the 1050-
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Figure 2. Plot of initial dose vs meprobamate concentration for the population.  
Average concentration was 29,344 ng/mL.  Orange is 25-50% range of meprobamate 
concentration and gray is 50-75% range of meprobamate concentration 
 
For the final dose of carisoprodol prescribed to patients (Figure 3), the minimum 
reported concentration of meprobamate was also as low as 500 ng/mL and a maximum 
concentration of 336,853 ng/mL.  The median concentration for the final dose category 
was 28,389 ng/mL.  It’s important to note that though the maximum and minimum 
concentrations for both initial and final doses are the same, this is due to only one 
meprobamate concentration in a urine specimen being reported per patient, where the 
dose at which some patients ingested carisoprodol changed throughout their treatment.  
Certain patients had urine samples collected on more than one occasion, yet only one 
meprobamate concentration was reported.  Of the 1,672 patients in the overall population 
of this study, 101 patients had a final dose in the 0-300 mg dosing range, 508 patients had 
a final dose in the 350-700 mg range, 665 patients had a final dose in the 700-1050 mg 
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range, 360 patients had a final dose in the 1050-1400 mg range and 38 patients had a final 




Figure 3. Plot of final dose vs meprobamate concentration for the population.  
Average concentration was 28,389 ng/mL.  Orange is 25-50% range of meprobamate 
concentration and gray is 50-75% range of meprobamate concentration 
 
3.1.3 Dosing for Male Population 
For the male population, some patients had an initial dosing of carisoprodol of 0 
mg (meaning they did not initially take the drug in their treatment) and one particular 
patient had an initial dose of 4200 mg.  The average initial dose of the male population 
was 713.5 mg (0-4200 mg range) with a median initial dose of 700 mg of carisoprodol.  
Of the 605 males in the study, 167 males fell into the first dosing range of 0-300 mg 
(27.6%), 162 males in the dosing range of 350-700 mg (26.8%), 166 males in the dosing 
range of 700-1050 mg (27.4%), 99 males in the 1050-1400mg dosing range (16.4%) and 
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10 males with a dose greater than 1400 mg (1.7%).   Of the male initial dosing 
population, the minimum concentration of meprobamate reported for a urine specimen 
was 530 ng/mL and a maximum meprobamate concentration of 292,133 ng/mL, both of 
which were from patients in the 0-300 mg dosing category.  The average meprobamate 
concentration in urine samples for the male population initial dose was 28,527 ng/mL 
(530-292,133 ng/mL range).  Figure 4 details the initial dose of the male population vs 





Figure 4: Plot of male population’s initial carisoprodol dose range vs resulting 
meprobamate concentration.  Average concentration of meprobamate was 28,527 
ng/mL.  Orange is 25-50% range of meprobamate concentration and gray is 50-75% 
range of meprobamate concentration 
 
The average final dose for the male population was 957.3 mg (0-4200 mg range) 
and a median final dose of 1050 mg, equivalent to taking a 350 mg prescription of 
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carisoprodol three times daily.  Of the 605 males in the study, 35 fell into the 0-300 mg 
final dosing range (5.8%), 196 males in the 350-700 mg dosing range (32.4%), 223 males 
in the 700-1050 mg final dosing range (36.8%), 131 males in the 1050-1400 mg dosing 
range (21.7%) and 20 males who had a final carisoprodol dose in the >1400 mg dosing 
range (3.3%).  The average meprobamate concentration for the male population was 
26,466 ng/mL (530-292,133 ng/mL range).  Figure 5 details the final dose of male 
population vs the reported meprobamate concentration. 
 
 
Figure 5: Plot of male population’s final carisoprodol dose range vs resulting 
meprobamate concentration.  Average Concentration of meprobamate was 26,466 
ng/mL.  Orange is 25-50% range of meprobamate concentration and gray is 50-75% 
range of meprobamate concentration 
 
3.1.4 Dosing for Female Population 
The average initial dose for females was 717.1 mg (0-2100 mg range) and the 
median dose was 700 mg, equivalent to a 350 mg prescribed dose twice a day.  Of the 
1,067 females in the study, 280 females had an initial dose in the 0-300 mg dosing range 
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(26.2% of the population), 257 females had an initial dose in the 350-700 mg dosing 
range (24.1%), 349 females had an initial dose in the 700-1050 mg dosing range (32.7%), 
171 females had an initial dose in the 1050-1400 mg dosing range (16.1%) and 10 
females had an initial dose >1400 mg (<1%).  The average meprobamate concentration in 
the female initial dose category was 26,969.2 ng/mL (500 - 336,853 ng/mL range), which 
can be seen in Figure 6. 
 
Figure 6: Plot of female population’s initial carisoprodol dose range vs resulting 
meprobamate concentration.  Average concentration of meprobamate was 26,692.2 
ng/mL.  Orange is 25-50% range of meprobamate concentration and gray is 50-75% 
range of meprobamate concentration 
 
The average final dose for females was 939.6 mg (0-5250 mg range) and the 
median final dose was 1050 mg.  Of the 1,067 females in the study, 66 females had a 
final dose in the 0-300 mg dosing range (6.2%), 312 females had a final dose in the 350-
700 mg dosing range (29.2%), 442 females had a final dose in the 700-1050 mg dosing 
range (41.4%), 229 females had a final dose in the 1050-1400 mg dosing range (21.5%) 
 
  22 
and 18 females had a final dose >1400 mg (1.7%).  The average reported meprobamate 
concentration for the final dose category was 26,381.4 ng/mL (500 -336,843 ng/mL 
range) as seen in Figure 7. 
 
Figure 7: Plot of female population’s final carisoprodol dose range vs resulting 
meprobamate concentration.  Average concentration of meprobamate was 26,381.4 
ng/mL.  Orange is 25-50% range of meprobamate concentration and gray is 50-75% 
range of meprobamate concentration 
 
 
3.2. BMI  
3.2.1 Overall Population BMI 
The population of this study was split into three BMI categories: underweight, 
normal, and obese (Table 1).  Using equation 1 comparing each patient in the 
population's weight to the square of their height, the following breakdown of each 
category was observed: 51 patients were considered underweight (3.1%), 442 patients 
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were considered normal weight (26.4%), and 1179 patients were considered overweight 
(70.5%).  Respectively for each BMI category, average meprobamate concentrations for 
underweight, normal and, overweight categories were 42,914 ng/mL (586-336,853 
ng/mL range), 34,258 ng/mL (500-307,786 ng/mL range) and 25,168 ng/mL (515-
267,419 ng/mL range) as shown in Figure 8. 
 
Figure 8: Plot of overall population BMI categories vs reported meprobamate 
concentration.  Average meprobamate concentrations were 49,914 ng/mL 
(underweight), 34,258 ng/mL (normal) and 25,168 ng/mL (overweight).  Orange is 25-
50% range of meprobamate concentration and gray is 50-75% range of meprobamate 
concentration 
 
3.2.2 Male Population BMI 
Of the 605 male patients in this study, 6 patients fell into the underweight BMI 
category (1%), 156 patients fell into the normal BMI category (25.8%), and the 
remaining 443 patients fell into the overweight BMI category (73.2%).  For the entire 
male population, the average meprobamate concentration found in urine samples was 
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30,434 ng/mL (530-292,133 ng/mL).  For each BMI category, the average meprobamate 
concentration was 31,597 ng/mL (1,010-111,037 ng/mL range) for underweight patients, 
36,122 ng/mL (669-292,133 ng/mL range) for normal BMI patients and 23,583 ng/mL 
(530-267,419 ng/mL range) for overweight patients. (Figure 9).  
 
Figure 9: Plot of male population BMI categories vs reported meprobamate 
concentration.  Average meprobamate concentrations were 31,597 ng/mL 
(underweight), 36,122 ng/mL (normal) and 23,583 ng/mL (overweight).  Orange is 25-




3.2.3 Female Population BMI 
 Of the 1,067 female patients in this study, 45 females fell into the underweight 
BMI category (4.2%), 286 females fell into the normal BMI category (26.8%), and 736 
females fell into the overweight BMI category (69.0%).  For the entire female population, 
the average reported meprobamate concentration found in urine samples was 34,595 
ng/mL (500-336,853 ng/mL range).  For each BMI category, the average meprobamate 
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concentration was 44,423 ng/mL (586-336,853 ng/mL range) for underweight patients, 
33,242 ng/mL (500-307,786 ng/mL range) for normal weight patients and 26,122 ng/mL 
(515-251,853 ng/mL range) for overweight patients (Figure 10). 
 
Figure 10: Plot of female population BMI categories vs reported meprobamate 
concentration.  Average meprobamate concentrations were 44,423 ng/mL 
(underweight), 33,242 ng/mL (normal) and 26,122 ng/mL (overweight).  Orange is 25-




3.3 Overall Population Age Ranges 
3.3.1 Ages 20-29 
 The population in this study contains 20 patients between the ages of 20 and 29, 
1.2% of the overall population.  Of those 20 patients, 9 were male and 11 were female.  
The average meprobamate concentration was 31,852 ng/mL (1,094-112,153 ng/mL 
range) with a median meprobamate concentration of 19,397 ng/mL. 
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3.3.2 Ages 30-39 
 The population in this study contains 143 patients between the ages of 30 and 39, 
8.6% of the overall population.  Of those 143 patients, 41 were male and 102 were 
female.  The average meprobamate concentration for this age range was 30,111 ng/mL 
(548-336,853 ng/mL range) and the median meprobamate concentration was 16,014 
ng/mL. 
3.3.3 Ages 40-49  
 The population in this study contains 321 patients between the ages of 40 and 49, 
19.2% of the overall population.  Of those 321 patients, 108 were male and 213 were 
female.  The average meprobamate concentration for this age range was 30,381 ng/mL 
(515-251,853 ng/mL range) and the median concentration of meprobamate was 18,629 
ng/mL.  
3.3.4 Ages 50-59  
 The population in this study contains 607 patients between the ages of 50 and 59, 
36.3% of the overall population.  Of those 607 patients, 225 were male and 382 were 
female.  The average meprobamate concentration reported for this age range was 29,434 
ng/mL (530-292,133 ng/mL range) and the median meprobamate concentration reported 
was 17,801 ng/mL. 
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Figure 11: Plot of population age range categories vs meprobamate 
concentration.  Orange is 25-50% range of meprobamate concentration and gray is 
50-75% range of meprobamate concentration 
 
3.3.5 Ages 60-69 
 The population in this study contains 463 patients between the ages of 60 and 69, 
27.7% of the overall population.  Of these 463 patients, 180 were male and 283 were 
female.  The average meprobamate concentration for this age range was 25,115 ng/mL 





  28 
3.3.6 Ages 70-79 
 The population in this study contains 101 patients between the ages of 70 and 79, 
6.0% of the overall population.  Of those 101 patients, 38 were male and 63 were female.  
The average meprobamate concentration for this age range was 22,490 ng/mL (500-
176,325 ng/mL range) and the median meprobamate concentration was 13,418 ng/mL. 
3.3.7 Ages 80+  
 The population in this study contains 17 patients above the age of 80, 1.0% of the 
overall population. Of those 17 patients, 4 were male and 13 were female.  The minimum 
reported meprobamate concentration for this age range was 1,629 ng/mL and the 
maximum meprobamate concentration was 108,781 ng/mL.  The average meprobamate 
concentration for this age range was 23,393 ng/mL and the median meprobamate 
concentration was 13,344 ng/mL.  
 
3.4 SVT  
3.4.1 Initial sample screening  
 All samples included in this study used SVT to determine the number of samples 
that fell outside normal human characteristics.  Of the 1,672 patients that were included 
in the study after dropping incomplete entries, 44 patients (2.6%) had been flagged for 
samples that were either invalid or diluted based on the SVT parameters.  Of the 44 
patients, 14 patients were male, and 30 patients were female. Of the 44 samples that were 
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flagged, 21 were considered invalid, 22 were considered diluted and 1 sample cited 
oxidant activity that may result in lower concentrations of certain drugs or a negative test 
when the drug had been present.  Of the 44 flagged samples, five included the presence of 
an illicit drug, but did not specify which illicit drug/drugs were present.  Figure 11 details 
the SVT results for samples that were of interest for patients in this study.  
 
 
Figure 12: SVT results for patient population detailing initial failing samples along 
with secondary screening of pH, creatinine, specific gravity, and illicit substance 
present 
 
3.4.2 Failed pH parameter 
 A secondary evaluation of the 1,672 patient data was conducted to determine if 
there were additional samples that did not pass the SVT parameters listed in Table 4.  For 
the pH parameter, 16 males and 77 females had pH values outside of 4.5-8.0 range.  
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were deemed to fail pH parameter failed on the high end of the pH scale (> 8.0).  Of the 
93 samples, 11 had already been labeled as invalid or dilute from the initial screening 
process, meaning a further 82 samples failed the pH parameter.  Of the 77 females with a 
pH value greater than 8.0, the average meprobamate concentration was 26,003 ng/mL 
(989-107,966 ng/mL range) and of the 16 males the average meprobamate concentration 
was 48,609 ng/mL (5,733-121,738 ng/mL range). 
3.4.3 Failed Creatinine parameter 
 Using Table 4, a sample was deemed to have failed SVT creatinine parameter if 
the value was less than 20 mg/dL.  Creatinine values below this threshold are considered 
diluted and samples below 5 mg/dL are considered to be inconsistent with human 
urine.20,21  Of the 1,672 patients in this study population, 107 had creatinine values below 
the 20 mg/dL, 6.4% of the overall population.  Of the 107 patients that failed the 
creatinine parameter, 25 were males and 82 were females.  Of the samples flagged in the 
initial SVT screening that had failed the creatinine parameter, 33 were included in this set 
of data analysis and 64 samples were also included in the secondary screening process. 
Of the failed creatinine parameter population, the average meprobamate concentration 
was 10,957 ng/mL (541-84,305 ng/mL range). 
3.4.4 Failed Specific Gravity parameter 
A sample is deemed to fail the SVT specific gravity parameter if the value falls 
outside the range of 1.002-1.020.  Of the 1,672 patients in the study, a total of 32 patients 
failed the specific gravity parameter, 1.9% of the overall population.  Of these 32 
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patients, 14 were males and 18 were females.  In total, 13 of the 32 samples were flagged 
in the initial SVT screening, 10 of which failed were below 1.002 and three which were 
over 1.020.  The average meprobamate concentration for samples that failed on the low 
end of the specific gravity threshold was 9,322 ng/mL (541-20,616 ng/mL range) and the 
average meprobamate concentration for samples that failed on the high end of the 
specific gravity threshold was 28,880 ng/mL (515-81,920 ng/mL range).  
3.4.5 Illicit drug detection 
Patients who indulge in illicit drug use that also must provide urinalysis samples 
will often try to substitute, adulterate or dilute their samples in an attempt to hide their 
drug use.  Of the 1,672 patients in this study, 163 had an illicit drug present in their urine 
specimen submitted for analysis (9.7% of the population).  The patients who had an illicit 
substance in their urine included 67 males and 96 females. Only 5 of these samples were 
initially flagged as samples that were invalid or dilute.  The average meprobamate 
concentration of those samples that had an illicit substance present was 29,446 ng/mL 
(515-187,909 ng/mL range) for the entire population with a median concentration of 
16,836 ng/mL.  The female patients who had an illicit substance in their urine sample had 
an average meprobamate concentration of 29,432 ng/mL (515-187,909 ng/mL range) and 
a median concentration of 16,182 ng/mL.  The male patients who had an illicit substance 
in their urine sample had an average meprobamate concentration of 29,446 ng/mL (682-
159,149 ng/mL range) and a median concentration of 17,421 ng/mL.  
 
 
  32 
4. DISCUSSION 
Carisoprodol and its primary metabolite meprobamate have been utilized to treat 
anxiety for therapeutic means since the late 1950’s and are still used today.  Therapeutic 
drug monitoring and urine drug testing are used in compliance settings to ensure that 
abuse of the drug does not occur as it did quite frequently in the early years of its 
distribution and use.1,2  Though carisoprodol and meprobamate prescriptions have 
decreased overall due to the introduction of BZDs as a safer and less abusive alternative, 
therapeutic use is still relevant so long as doctors and patients ensure dosing regimens are 
followed correctly.  The amount of meprobamate detected on average in this study for the 
entire population was 28,112 ng/mL which is lower when compared to a similar study 
that looked at pain medication concentrations in urine samples (mean of 40,700 ng/mL 
for meprobamate).18 
4.1 Patient Population Size 
Patients who were prescribed carisoprodol were predominantly female in this study at 
almost a 2:1 ratio.  The female population had 465 more patients than the male 
population 1,067 patients (63.8%) to 605 patients (36.2%) respectively. This distribution 
across genders closely follows a recent study of carisoprodol use in Norway.29  That 
study compared 83,713 patients and characterized them into 5 groups depending on their 
level of compliance with defined daily dose of carisoprodol (ranging from therapeutic use 
of carisoprodol to abuse of pain and opioid medications).  In the study 62% of patients 
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used carisoprodol as therapeutic treatment and had a similar population distribution of 2:1 
in favor of female patients being prescribed carisoprodol.29 
 
4.2 Dosing 
For the entire patient population, the average initial dose of carisoprodol was 700 mg 
(0-4200 mg range) which then increased to 946 mg (0-5250 mg range) for the final dose.  
When considering the median dose, it meant that the population typically would start 
with an initial dose of about two 350 mg carisoprodol tablets per day which would then 
increase to three 350 mg carisoprodol tablets per day for a final dose as therapy with this 
drug continued.  As 556 of the 1,672 patients (33.3%) of this study had dosing ranges 
between 700-1050 mg, it supports dosing in this range would be most beneficial to 
patients using carisoprodol for therapeutic treatment.  Common dosing strategies can be 
either fixed dosing where a person takes a particular dose over a period of time or based 
on their weight where larger doses are taken by patients with a larger BMI.  The problem 
with these types of dosing strategies is that it is dependent upon the patient whether the 
regimen is followed consistently and in the correct manner, particularly with drugs that 
have a tendency to be abused, similar to carisoprodol.31   
4.3 BMI 
The majority of the patients in this study fell into the overweight BMI category with 
1,179 of the 1,672 patients having BMI >25.0 (70.5% of the population).  Due to the 
large portion of the population falling into this category, it is difficult to see statistically 
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significant meprobamate concentration as the mean meprobamate concentration for this 
class of BMI (25,168 ng/mL with a range of 515-267,419 ng/mL) was lower than the 
normal (34,258 ng/mL with a range of 500-307,786 ng/mL) and underweight (42,914 
ng/mL with a range of 586-336,853 ng/mL) categories.  This can be attributed to having 
such a large population being included in the overweight category with the normal weight 
patients occupying 442 of the 1,672 patients (26.4% of population), only a third of the 
overweight population.  This resulted in a 9,090 ng/mL greater average meprobamate 
concentration for normal weight category (Figure 8) than the overweight category. 
 
4.4 Age Ranges 
Carisoprodol was most commonly prescribed to patients in this study who were 
between the ages of 50 and 59 with 607 patients (36.3% of the total population).  Based 
on the data reported in this study, the majority of the patient population prescribed 
carisoprodol were between the ages of 40 and 69, with 513 males (84.5% of male 
population) and 878 females (82.3% of female population).  The lack of patients outside 
of these age ranges, particularly patients aged 20-29 and above 80 shows that adverse 
effects and abuse potential could be important factors in considering other forms of 
treatment for patients in those age ranges.  
 
4.5 SVT 
The patient data provided a section where comments were made based on SVT 
parameters to determine if a given sample was diluted or considered invalid. Samples in 
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this study, however, did not carry a comment for failing a particular SVT parameter but 
still had one or more parameters that fell outside the acceptable threshold.  This expanded 
the original 44 samples, which included a comment, to 305 samples that had at least one 
failed parameter or the inclusion of an illicit substance, totaling 18.2% of the population 
in this study.  Importantly, patients who submitted urinalysis samples may not have been 
intentionally diluting their sample since the number of illicit drugs present in the 
population totaled 152, almost exactly half of the samples flagged in the secondary SVT 
filtering of patient samples.  False negatives in UDT can occur when patients add or 
ingest ingredients (sodium chloride, vinegar or bleach) or when commercial additives 
(peroxidases, glutaraldehyde) are included in a submitted sample.  Other false negatives 
in UDT occur with poor cross reactivity in UDT immunoassays and less common drugs 
or metabolites being tested (ex. codeine normally tested for, but hydrocodone, a 
metabolite of codeine, may not be detected).  False positive results can occur with drug 
interactions of over the counter or other prescribed medications reacting with the 
immunoassay due to structural similarities in compounds (ex. ibuprofen has been 
reported to result in false THC positive).30 
 
5. CONCLUSIONS 
Meprobamate use as a means of treating anxiety closely mimics barbiturate effects 
and has a potential for abuse but is maintained as an anxiolytic prescribed by doctors in 
the form of carisoprodol, an active drug and prodrug of meprobamate. This research 
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illustrates the UDT concentrations of meprobamate resulting from use of carisoprodol as 
a means of therapeutic drug treatment as an anxiolytic.  The data that were presented in 
this study displays differences and similarities in dosing, age, BMI and SVT parameters 
of submitted urinalysis samples for those prescribed carisoprodol.  The data in this study 
can be used to monitor anxiety therapy through urine specimen testing to determine 
whether carisoprodol is being adhered via resulting meprobamate concentrations.  These 
data can be used as a tool to help determine both adherence and/or abuse of carisoprodol 
for a patient based on their age and BMI. 
 
Future Directions 
 Continuation of this study could be beneficial in terms of evaluating therapeutic 
use of carisoprodol and monitoring its primary metabolite meprobamate as well as 
determining the number of patients who may abuse it.  It would be important to add to the 
population in this study to get a better understanding of the trends between dosing and 
meprobamate urine concentrations.  This information would be of benefit to medical 
professionals who are considering prescribing a patient carisoprodol to know the 
percentage of patients who abuse it, their ages, BMI as well as collect preliminary 
urinalysis samples prior to dosing to gather baseline information.  Another change that 
could be implemented in future studies would be to collect the same number of urine 
specimen for each patient or to collect samples at defined increments of the patients’ 
treatment with carisoprodol.  This would be beneficial as in this analysis of data, only 
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some patients had multiple urine samples collected but still only had one reported 
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